Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Iowa for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Iowa only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Iowa (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Abdelaziz Elhaddad (NPI 1447488325)

Field	Value
Entity Type	Individual
Organization	Abdelaziz Elhaddad
Address	411 Laurel St Ste A300
City	Des Moines
State	IA
ZIP	50314
Taxonomy	Medical Oncology Physician
NPI Enumerated	June 30, 2009

Payer Source	Total Paid
Medicare	$1.5M
Medicaid	$0

Key Findings

ABDELAZIZ ELHADDAD is a Medical Oncology Physician based in DES MOINES, IA with lifetime Medicare revenue of $1.5M and no Medicaid billing on file; this profile is effectively single‑payer Medicare in scale and suggests limited exposure to Medicaid populations or contracts. The provider's NPI was enumerated 2009-06-30 (~17 years ago), indicating an established practice tenure in the market.

Revenue is highly concentrated in a small number of high-cost oncology drugs: the precomputed top‑3 Medicare codes account for 73.0% of total Medicare revenue, driven primarily by J9271 (Injection, pembrolizumab) at $782.6K (55.7% of Medicare revenue), followed by J9264 at $137K (9.7%) and J0897 at $106.9K (7.6%). This concentration indicates that a single biologic immunotherapy (pembrolizumab) dominates the practice's reimbursement footprint.

Clinical and service-line mix is consistent with an outpatient oncology infusion practice that delivers systemic anti-cancer therapy and associated monitoring: the dominant code J9271 (pembrolizumab) along with chemotherapy agents J9264 (paclitaxel protein-bound) and add-on/infusion codes such as 96413, 96365, 96417 and G0498 show in-office administration of immunotherapy and cytotoxic chemotherapy as core services. Complementary lab work (80053, 85025, 84443) and supportive medications (J0881 darbepoetin, J0897 denosumab, J0185 aprepitant, J1569 immune globulin) point to integrated treatment and toxicity-management workflows.

Competitive standing across the major drug codes is mixed: J9271 ranks #493 of 1841 providers (73th percentile; typical, unremarkable volume), J9264 ranks #21 of 118 providers (83th percentile; typical, unremarkable volume), and J0897 ranks #2331 of 10057 providers (77th percentile; typical, unremarkable volume). These rank/percentile labels indicate participation at or above median national volumes for key chemotherapy and supportive drugs but do not suggest dominant national leadership for pembrolizumab.

Office evaluation-and-management (E/M) activity is notable relative to national peers: 99214 generated $81.5K from 906 claims and ranks #14603 of 479517 providers (97th percentile; notably above typical national volume), while 99213 and 99215 also appear in the top codes. The elevated 99214 percentile suggests substantial longitudinal outpatient management of established oncology patients in addition to infusion visits.

Operationally, claim counts show substantial throughput for key infusion items: J9271 appears with 18.2K claims and J9264 with 13.7K claims, indicating high-frequency administration of these agents in this provider's billing. This claim-level volume, coupled with long tenure since 2009-06-30 (~17 years ago), supports the interpretation of an experienced infusion practice rather than a low-volume episodic prescriber.

Although most drug and infusion codes are described as typical or unremarkable in volume relative to national peers, there are a few lower-percentile signals for certain supportive agents—e.g., J1569 ranks #468 of 542 providers (13th percentile; typical, unremarkable volume)—which may reflect practice preference, formulary choices, or patient-mix differences rather than systematic deviation. Taken together, the coding pattern is consistent with routine oncology treatment protocols and supportive-care practice rather than anomalous billing behavior.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

65 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	18,200	$40	$782.6K
J9264	Injection, paclitaxel protein-bound particles, 1 mg	13,700	$10	$137K
J0897	Injection, denosumab, 1 mg	5,940	$20	$106.9K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	910	$90	$81.5K
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	1,380	$40	$48.3K
J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)	21,130	$1	$42.3K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	400	$90	$38K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	470	$60	$29.3K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	180	$130	$23.3K
J9217	Leuprolide acetate (for depot suspension), 7.5 mg	100	$130	$13.1K

Showing 1–10 of 65

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 65 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Iowa Distribution

Abdelaziz Elhaddad — 4 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Iowa

Full comparison — all codes billed, vs. state median

65 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	13	30	17,200	$40	$902.3K
J1569	9	10	2,680	$40	$133.6K
J9264	2	10	13,700	$10	$133.2K
J0897	34	190	1,920	$20	$74.1K
J0881	4	10	15,520	$1	$43.2K
96413	17	80	210	$90	$24K
J9217	40	50	140	$130	$23.4K
J0185	7	20	6,890	$1	$14.5K
99214	107	4,690	100	$70	$14.4K
99233	676	910	60	$90	$10.5K

Showing 1–10 of 65

Related Providers

Other providers that share a Tax Identification Number (TIN) with Abdelaziz Elhaddad, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Dallas County Hospital District	TX	General Acute Care Hospital	$0	$152.8M
State University Of Iowa	IA	Family Medicine Physician	$0	$103.8M
State University Of Iowa	IA	General Acute Care Hospital	$0	$90.4M
State University Of Iowa	IA	Dentist	$0	$25.8M
Thomas Buroker	IA	Medical Oncology Physician	$9.4M	$0
Kyle Alliman	IA	Ophthalmology Physician	$8.7M	$0
Alex Kartvelishvili	IA	Ophthalmology Physician	$8.1M	$0
Paul Boeke	IA	Ophthalmology Physician	$7.1M	$0
Austin Strohbehn	IA	Retina Specialist (Ophthalmology) Physician	$5.8M	$0
Jeremy Deutsch	KS	Hematology & Oncology Physician	$5.7M	$0

Nearby Providers

Other providers in the same ZIP code as Abdelaziz Elhaddad, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Broadlawns Medical Center	IA	General Acute Care Hospital	$0	$112.9M
Catholic Health Initiatives-iowa Corp	IA	General Acute Care Hospital	$0	$26.4M
Des Moines Independent Community School District	IA	Local Education Agency (LEA)	$0	$22.8M
Primary Health Care, Inc.	IA	Federally Qualified Health Center (FQHC)	$0	$14.1M
Broadlawns Medical Center	IA	Community/Behavioral Health Agency	$0	$13.2M
Mercy Clinics Inc	IA	Pediatric Adolescent Medicine Physician	$0	$10.7M
Des Moines River Physicians, LLC	IA	Emergency Medicine Physician	$0	$8.1M
Catholic Health Initiatives-iowa Corp	IA	Clinical Medical Laboratory	$0	$8M
Primary Health Care, Inc.	IA	Federally Qualified Health Center (FQHC)	$0	$7.9M
Vita Health Services	IA	Intellectual and/or Developmental Disabilities Residential Treatment Facility	$0	$7.5M

Abdelaziz Elhaddad — Billing Profile & Reimbursement Data

Sign up for Abdelaziz Elhaddad — Billing Profile & Reimbursement Data policy alerts

Abdelaziz Elhaddad — Billing Profile & Reimbursement Data

Sign up for Abdelaziz Elhaddad — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References